- Home
- DATS vs EQ Comparison
DATS vs EQ Comparison
Compare DATS & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- EQ
- Stock Information
- Founded
- DATS 2014
- EQ 2017
- Country
- DATS United States
- EQ United States
- Employees
- DATS N/A
- EQ N/A
- Industry
- DATS Computer Software: Prepackaged Software
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- DATS Technology
- EQ Health Care
- Exchange
- DATS Nasdaq
- EQ Nasdaq
- Market Cap
- DATS 13.4M
- EQ 12.2M
- IPO Year
- DATS 2021
- EQ 2018
- Fundamental
- Price
- DATS $2.60
- EQ $0.32
- Analyst Decision
- DATS
- EQ Buy
- Analyst Count
- DATS 0
- EQ 3
- Target Price
- DATS N/A
- EQ $3.00
- AVG Volume (30 Days)
- DATS 375.4K
- EQ 1.8M
- Earning Date
- DATS 08-13-2025
- EQ 08-07-2025
- Dividend Yield
- DATS N/A
- EQ N/A
- EPS Growth
- DATS N/A
- EQ N/A
- EPS
- DATS N/A
- EQ N/A
- Revenue
- DATS $388.00
- EQ $30,406,000.00
- Revenue This Year
- DATS N/A
- EQ N/A
- Revenue Next Year
- DATS N/A
- EQ N/A
- P/E Ratio
- DATS N/A
- EQ N/A
- Revenue Growth
- DATS N/A
- EQ N/A
- 52 Week Low
- DATS $1.04
- EQ $0.27
- 52 Week High
- DATS $9.34
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- DATS 49.04
- EQ 43.51
- Support Level
- DATS $2.40
- EQ $0.27
- Resistance Level
- DATS $2.80
- EQ $0.36
- Average True Range (ATR)
- DATS 0.18
- EQ 0.04
- MACD
- DATS -0.02
- EQ 0.00
- Stochastic Oscillator
- DATS 33.64
- EQ 56.67
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.